1. Home
  2. QNC vs MYGN Comparison

QNC vs MYGN Comparison

Compare QNC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$2.22

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$3.28

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
MYGN
Founded
2007
1991
Country
Canada
United States
Employees
5
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
444.2M
IPO Year
2026
1996

Fundamental Metrics

Financial Performance
Metric
QNC
MYGN
Price
$2.22
$3.28
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$7.64
AVG Volume (30 Days)
621.4K
2.3M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$6.86
Revenue Next Year
N/A
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$1.90
$2.74
52 Week High
$3.59
$8.59

Technical Indicators

Market Signals
Indicator
QNC
MYGN
Relative Strength Index (RSI) 44.07 29.53
Support Level $1.91 $2.74
Resistance Level $2.31 $5.17
Average True Range (ATR) 0.13 0.29
MACD 0.04 -0.25
Stochastic Oscillator 78.05 16.98

Price Performance

Historical Comparison
QNC
MYGN

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: